Genentech/OSI Tarceva Lung Cancer Trial Modified Following “Safety Signal”
Executive Summary
A "safety signal" detected during Genentech's Phase III trial of Tarceva (erlotinib) for first-line combination therapy in non-small cell lung cancer will not impact the rest of the agent's development program, the company said April 9